In Situ Hybridization Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

The Global In Situ Hybridization Market is segmented by Product (Analytical Instruments, Kits and Reagents, Software and Services, and Other Products), Technique (Fluorescence In Situ Hybridization(FISH), and Chromogenic In Situ Hybridization(CISH)), Application (Cancer, Infectious Diseases, and Other Applications), End User (Diagnostics Laboratories, Academic and Research Institutions, and Contract Research Organizations (CROs)), and Geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The report offers the value (in USD million) for the above-mentioned segments.

In-Situ Hybridization Market Size

In Situ Hybridization Market Summary

Compare market size and growth of In Situ Hybridization Market with other markets in Healthcare Industry

In-Situ Hybridization Market Analysis

The In Situ Hybridization Market is expected to register a CAGR of 7.2% during the forecast period.

The COVID-19 pandemic is expected to have a significant effect on the market. To keep pace with increased testing norms to detect suspected cases of COVID-19, with the emergence of the SARS-CoV-2 virus, already increased lab testing demand grew even more across the world. For instance, the article published in Nature Journal in October 2021 mentioned that a rapid fluorescence in situ hybridization protocol capable of detecting SARS-CoV-2 specifically and quantitatively in approximately 20 minutes in virus cultures combined nasal and throat swabs with added virus and likely patient samples with added virus and likely patient samples without previous purifications. Such proven efficacy of in situ hybridizations in the diagnosis of COVID-19 infection significantly impacted the market growth during the pandemic period. Also, the demand for in situ hybridization is expected to remain intact due to the emergence of various mutant strains of the SARS-CoV-2 virus during the post-pandemic period, thereby driving the growth of the market during the forecast period.

The increasing incidence of cancer, infectious diseases, and genetic disorders and the growing awareness of cancer therapeutics are the major drivers for the growth of the in-situ hybridization market. For instance, the Global Flu data published in February 2022 mentioned that an estimated 1 billion people worldwide are infected by seasonal influenza yearly. The report also mentioned that out of those 1 billion, about 3 to 5 million people have a severe case of flu every year. Likewise, the report published by the World Health Organization in November 2021 reported that more than 1.0 million sexually transmitted infections are acquired globally, and most of them are asymptomatic. It also reported that every year there are an estimated 374.0 million new infections, with 1 out of 4 sexually transmitted infections: gonorrhea, chlamydia, trichomoniasis, and syphilis. 

Additionally, as per the WHO factsheet published in February 2022, in 2021, there were an estimated 1.9 million new cancer cases diagnosed in the United States. The report also mentioned that each year, approximately 400,000 children develop cancer globally. Cervical cancer is the most common in 23 countries, such as Eswatini, India, South Africa, Latin America, and others. The most common cancers are breast, lung, colon, rectum, and prostate. Such rising cases of infectious diseases and cancer across the world are expected to drive the demand for advanced and effective diagnosis, thereby contributing to the growth of the market over the forecast period.

Additionally, the rising market players' initiatives, such as partnerships, acquisitions, and mergers to develop in situ hybridization techniques, are also expected to propel the market's growth. For instance, in March 2021, Bio SB announced that through its partnership agreement with ZytoVision, it would distribute a line of CE-approved chromogenic in situ hybridization and fluorescent in situ hybridization probes targeted for use in lung carcinomas.

However, the lack of skilled professionals to perform advanced procedures is expected to restrain the market's growth over the forecast period.

In-Situ Hybridization Industry Overview

The In Situ Hybridization Market is fragmented and competitive. The major players operating globally in the In Situ Hybridization Market are Abnova Corporation, Agilent Technologies Inc., F. Hoffmann-La Roche Ltd, Biocare Medical LLC., Genemed Biotechnologies Inc., Thermo Fisher Scientific Inc., Biogenex Laboratories, Zytomed Systems GmbH, Creative Bioarray, and Bio SB Inc.

In-Situ Hybridization Market Leaders

  1. Agilent Technologies,Inc.

  2. Biocare Medical,LLC.

  3. F. Hoffmann-La Roche Ltd.

  4. Genemed Biotechnologies, Inc.

  5. Thermo Fisher Scientific

  6. *Disclaimer: Major Players sorted in no particular order
Need More Details on Market Players and Competiters?
Download PDF

In-Situ Hybridization Market News

  • September 2022: Vizgen launched Merscope Protein co-detection kits. This kit enables the measurement of subcellular spatial multi-omics by co-detecting RNA and proteins during standard Multiplexed Error-Robust Fluorescence in Situ Hybridization (MERFISH) experiment.
  •  May 2022: Leica Biosystems launched a high-speed in situ hybridization staining platform. Universal access enables laboratory technicians to load slides in any combination with any reagent at any time and seamlessly adapt to incoming workflows.

In-Situ Hybridization Market Report - Table of Contents

1. INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Prevalence of Cancer, Infectious Diseases and Genetic Disorders
    • 4.2.2 Advancements in Diagnostic Tools
    • 4.2.3 Rising Awareness on Cancer Therapeutics
  • 4.3 Market Restraints
    • 4.3.1 Lack of Skilled Personnel
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5. MARKET SEGMENTATION (Market Size by Value - USD Million)

  • 5.1 By Product
    • 5.1.1 Analytical Instruments
    • 5.1.2 Kits and Reagents
    • 5.1.3 Software and Services
    • 5.1.4 Other Products
  • 5.2 By Technique
    • 5.2.1 Fluoresence In Situ Hybridization (FISH)
    • 5.2.2 Chromogenic In Situ hybridization (CISH)
  • 5.3 By Application
    • 5.3.1 Cancer
    • 5.3.2 Infectious Diseases
    • 5.3.3 Others
  • 5.4 By End User
    • 5.4.1 Diagnostics Laboratories
    • 5.4.2 Academic and Research Institutions
    • 5.4.3 Contract Research Organizations (CROs)
  • 5.5 Geography
    • 5.5.1 North America
    • 5.5.1.1 United States
    • 5.5.1.2 Canada
    • 5.5.1.3 Mexico
    • 5.5.2 Europe
    • 5.5.2.1 Germany
    • 5.5.2.2 United Kingdom
    • 5.5.2.3 France
    • 5.5.2.4 Italy
    • 5.5.2.5 Spain
    • 5.5.2.6 Rest of Europe
    • 5.5.3 Asia-Pacific
    • 5.5.3.1 China
    • 5.5.3.2 Japan
    • 5.5.3.3 India
    • 5.5.3.4 Australia
    • 5.5.3.5 South Korea
    • 5.5.3.6 Rest of Asia-Pacific
    • 5.5.4 Middle-East and Africa
    • 5.5.4.1 GCC
    • 5.5.4.2 South Africa
    • 5.5.4.3 Rest of Middle-East and Africa
    • 5.5.5 South America
    • 5.5.5.1 Brazil
    • 5.5.5.2 Argentina
    • 5.5.5.3 Rest of South America

6. COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Abnova Corporation
    • 6.1.2 Agilent Technologies Inc.
    • 6.1.3 F. Hoffmann-La Roche Ltd
    • 6.1.4 Biocare Medical LLC
    • 6.1.5 Genemed Biotechnologies Inc.
    • 6.1.6 Thermo Fisher Scientific Inc.
    • 6.1.7 Biogenex Laboratories
    • 6.1.8 Zytomed System GmbH
    • 6.1.9 Bio-Techne Corporation (Advanced Cell Diagnostics Inc.)
    • 6.1.10 Bio SB Inc.
    • 6.1.11 Bio-Techne
    • 6.1.12 Qiagen NV
    • 6.1.13 Perkin Elmer
    • 6.1.14 Abbott Laboratories
    • 6.1.15 Merck KgaA
  • *List Not Exhaustive

7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

In-Situ Hybridization Industry Segmentation

As per the scope of the report, it is a technique that allows precise localization of a specific segment of nucleic acid within a histologic section. It is a laboratory technique to localize a sequence of DNA or RNA in a biological sample. 

The In Situ Hybridization Market is segmented by Product (Analytical Instruments, Kits and Reagents, Software and Services, and Other Products), Technique (Fluorescence In Situ Hybridization(FISH), and Chromogenic In Situ Hybridization(CISH)), Application (Cancer, Infectious Diseases, and Other Applications), End User (Diagnostics Laboratories, Academic and Research Institutions, and Contract Research Organizations (CROs)), and Geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally. The report offers the value (in USD million) for the above segments.

By Product Analytical Instruments
Kits and Reagents
Software and Services
Other Products
By Technique Fluoresence In Situ Hybridization (FISH)
Chromogenic In Situ hybridization (CISH)
By Application Cancer
Infectious Diseases
Others
By End User Diagnostics Laboratories
Academic and Research Institutions
Contract Research Organizations (CROs)
Geography North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle-East and Africa GCC
South Africa
Rest of Middle-East and Africa
South America Brazil
Argentina
Rest of South America
Need A Different Region or Segment?
Customize Now

In-Situ Hybridization Market Research FAQs

What is the current In Situ Hybridization Market size?

The In Situ Hybridization Market is projected to register a CAGR of 7.2% during the forecast period (2025-2030)

Who are the key players in In Situ Hybridization Market?

Agilent Technologies,Inc., Biocare Medical,LLC., F. Hoffmann-La Roche Ltd., Genemed Biotechnologies, Inc. and Thermo Fisher Scientific are the major companies operating in the In Situ Hybridization Market.

Which is the fastest growing region in In Situ Hybridization Market?

Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2025-2030).

Which region has the biggest share in In Situ Hybridization Market?

In 2025, the North America accounts for the largest market share in In Situ Hybridization Market.

What years does this In Situ Hybridization Market cover?

The report covers the In Situ Hybridization Market historical market size for years: 2021, 2022, 2023 and 2024. The report also forecasts the In Situ Hybridization Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.

In-Situ Hybridization Industry Report

Statistics for the 2025 In Situ Hybridization market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. In Situ Hybridization analysis includes a market forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.

In-Situ Hybridization Market Report Snapshots

In Situ Hybridization Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)